Motesanib diphosphate in progressive differentiated thyroid cancer. - Wikidata - awgldk - TriplyDB

Motesanib diphosphate in progressive differentiated thyroid cancer.

Motesanib diphosphate in progressive differentiated thyroid cancer.

http://www.wikidata.org/entity/Q34791480

about

Angiogenesis-inhibitors for metastatic thyroid cancer Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications Molecular Targeted Therapies of Aggressive Thyroid Cancer Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib Sorafenib in metastatic thyroid cancer: a systematic review Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment Progress in molecular-based management of differentiated thyroid cancer Current status and future perspectives in differentiated thyroid cancer Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer Autophagy in thyroid cancer: present knowledge and future perspectives Loss of Rap1GAP in papillary thyroid cancer A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma.Medullary thyroid carcinoma: targeted therapies and future directions Update: the status of clinical trials with kinase inhibitors in thyroid cancer Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer Current concepts and future directions in differentiated thyroid cancer.Alternative medical treatment for radioiodine-refractory thyroid cancers.The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.Lessons from mouse models of thyroid cancer.Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers Update on thyroid cancer treatment.Molecular pathogenesis and targeted therapies in well-differentiated thyroid carcinoma Molecular pathogenesis and mechanisms of thyroid cancer A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.

P2860

Q24236743-99153118-0A9B-4404-AC1E-85F9AA048892 Q24644683-EA86C582-B9CF-437D-9B6F-25FF17DE704E Q24657761-6E4AE0A7-4EA5-4DE5-9099-3AF7574F430F Q26751274-8953DA89-02BB-4203-B48D-5364F1A6203D Q26764899-601DB569-6F53-4B77-9024-1A327A0CE3B9 Q26774734-5289C7C9-63C0-438F-AE01-9BDE24DDDD17 Q26821959-62164053-EA6B-44E5-8D5A-EDAAA91E6B45 Q26828884-90A2376F-ABE4-48D3-B121-6E8EFBB5C697 Q26862841-83B7F250-29BF-45E7-B930-6EEF83FC3DF5 Q26863326-A8EBEC0A-4D74-41EC-8E65-470BE4021EC0 Q26998914-AA1A46E1-17B6-4715-A790-38091A289B5C Q26999887-6358F7B6-60CA-4860-9A33-21B0C6B49A2E Q27024484-7C301CBA-95F8-475A-A30D-CB589E1DE881 Q27853396-89FDEAF1-534E-469F-836A-4FEBAA403DB8 Q28072655-B7BE357E-85C2-47A1-B124-6637D18884FD Q28086785-E5DAB46A-1337-4BF5-8C34-9C92533089F9 Q28569254-994CBD73-0B17-4AD6-96EF-5BBC1FE17223 Q30414010-2D09B40B-D20A-447B-9890-65C49FDAAE47 Q33276185-17D0A7E5-01B9-4639-BBB5-774C074DBF86 Q33397349-55A05B11-03D1-4203-B329-4A633736F108 Q33557376-5A94DFE5-50F5-45CC-8044-54CC6A29E7B0 Q33570056-CA6D82CE-9D12-4AFB-94C2-ED9E8C308C6D Q33632654-BE1CBB1C-CF37-4060-8DD0-7781FE4CCB89 Q33677589-3278121B-4061-4257-9C7C-4C112EA95789 Q33704599-8B3A8A5B-B9E5-4A0E-9005-8A4E196FC324 Q33770769-B7B66FE6-1C0A-4454-8591-FD65734BCF78 Q33819911-70FD77D9-9C67-41C2-A396-14103CCF824C Q33828690-8A6576E4-A607-4F4E-BC26-E13C960B222E Q33972047-D8243CB4-4215-40FB-96BB-124B22A486A6 Q33973831-74AC6A2C-DBB4-4597-B582-6A14BCF7CA3F Q33984845-DF795F8A-6788-46EA-B7A7-6575BE1C9CF9 Q34031293-9F193DB7-AB6D-4AC2-9AB9-DF1BA1D13477 Q34046157-C0C1B5F2-FF1A-4779-9A18-40EB9FC3F999 Q34123724-FCA202C1-7EE4-4559-8F66-FD6285E81FA1 Q34310219-662A4436-902B-4EA2-B0B8-55A95B30A25F Q34318833-33012C5D-9341-40BB-B308-3DA9C018F2D6 Q34329018-88036E7C-BF9A-4AB8-AC43-254FD231B75E Q34330748-1CE3E621-4C0B-4719-A2C4-D3F633A615CD Q34337865-C36C379F-D732-4BD4-BB8B-DDC8D063439B Q34538390-9C4194BF-AD23-4501-A8C4-75FA061D60AF

P2860

Motesanib diphosphate in progressive differentiated thyroid cancer.

http://www.wikidata.org/entity/Q34791480

description

2008 nî lūn-bûn

@nan

2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Motesanib diphosphate in progressive differentiated thyroid cancer.

@ast

Motesanib diphosphate in progressive differentiated thyroid cancer.

@en

Motesanib diphosphate in progressive differentiated thyroid cancer.

@nl

type

label

Motesanib diphosphate in progressive differentiated thyroid cancer.

@ast

Motesanib diphosphate in progressive differentiated thyroid cancer.

@en

Motesanib diphosphate in progressive differentiated thyroid cancer.

@nl

prefLabel

Motesanib diphosphate in progressive differentiated thyroid cancer.

@ast

Motesanib diphosphate in progressive differentiated thyroid cancer.

@en

Motesanib diphosphate in progressive differentiated thyroid cancer.

@nl

P1433

Q34791480-FA63EE96-5724-4793-9AEE-9A0888ADD8A7

P1476

Q34791480-65E0E44B-E8AA-42FB-87CC-EDFB32D6062D

P2093

Q34791480-183B99B3-D918-48C9-838B-C2F343B50E6E

Q34791480-2060B9B2-A242-4686-BD8A-AB391244D7E4

Q34791480-2FBBAC1D-BCF0-40FE-89BD-F6E86C5C509C

Q34791480-535466C5-E70B-4EF9-ADA6-F786ECC41137

Q34791480-69E17281-2501-4888-8587-3E01206C7AE6

Q34791480-7D084C2D-AFCD-4030-A08F-871C03CF1D60

Q34791480-901D2ACB-4BCD-48C6-9227-8D6D46C7E481

Q34791480-BA8033A1-D314-411D-A4B8-66D2244FF726

Q34791480-BDAF1131-9AD5-461D-AFBA-F142DAECFD9C

Q34791480-C1D8BAB8-45C2-481B-BD72-4B859E4CA165

P304

Q34791480-0A70C2CB-C7CE-40E0-9E12-B06DBE3D84C0

P31

Q34791480-14ECCB0D-1C5D-4953-BEE8-237DE59DB2AE

P356

Q34791480-09F74396-09C8-4105-9374-752E70EA6934

P407

Q34791480-A87EAF78-FCD2-4F91-821A-5768D234FAEF

P433

Q34791480-F2CDBA21-4712-4398-913A-17464549DFD1

P478

Q34791480-C96A953A-AC47-476A-9AA3-8EBECAD5BD50

P50

Q34791480-5E9262FD-5A80-4DDC-AFD7-68CCA337302D

Q34791480-76B13F71-23A5-4526-BF60-DE918DF03E4D

Q34791480-9958D279-580B-400D-8594-9A9895BD6C1B

P577

Q34791480-03EBA4D1-84F2-4701-870E-6D33E9E04FDF

P698

Q34791480-73D7D303-70BA-45CB-988C-3368A2CB4287

P356

P1433

The New England Journal of Medicine

P1476

Motesanib diphosphate in progressive differentiated thyroid cancer

@en

P2093

Daniel E Stepan

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Droz

http://www.w3.org/2001/XMLSchema#string

Lori J Wirth

http://www.w3.org/2001/XMLSchema#string

Martin J Schlumberger

http://www.w3.org/2001/XMLSchema#string

Michael Hofmann

http://www.w3.org/2001/XMLSchema#string

Michael J Eschenberg

http://www.w3.org/2001/XMLSchema#string

Motesanib Thyroid Cancer Study Group

http://www.w3.org/2001/XMLSchema#string

Renato G Martins

http://www.w3.org/2001/XMLSchema#string

Todd Juan

http://www.w3.org/2001/XMLSchema#string

Yu-Nien Sun

http://www.w3.org/2001/XMLSchema#string

P304

31-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA075853

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

359

http://www.w3.org/2001/XMLSchema#string

P50

Steven I. Sherman

P577

2008-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18596272

http://www.w3.org/2001/XMLSchema#string